These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31775019)

  • 1. Janus kinase inhibition for autoinflammation in patients with DNASE2 deficiency.
    Hong Y; Capitani M; Murphy C; Pandey S; Cavounidis A; Takeshita H; Nanthapisal S; Yasuda T; Bader-Meunier B; McCreary D; Omoyinmi E; Rao A; Booth C; Gilmour K; Sebire N; Shah N; Klein N; Bullock AN; Eleftheriou D; Uhlig HH; Brogan P
    J Allergy Clin Immunol; 2020 Feb; 145(2):701-705.e8. PubMed ID: 31775019
    [No Abstract]   [Full Text] [Related]  

  • 2. Janus kinase 1/2 inhibition for the treatment of autoinflammation associated with heterozygous TNFAIP3 mutation.
    Mulhern CM; Hong Y; Omoyinmi E; Jacques TS; D'Arco F; Hemingway C; Brogan PA; Eleftheriou D
    J Allergy Clin Immunol; 2019 Sep; 144(3):863-866.e5. PubMed ID: 31175876
    [No Abstract]   [Full Text] [Related]  

  • 3. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome.
    Vanderver A; Adang L; Gavazzi F; McDonald K; Helman G; Frank DB; Jaffe N; Yum SW; Collins A; Keller SR; Lebon P; Meritet JF; Rhee J; Takanohashi A; Armangue T; Ulrick N; Sherbini O; Koh J; Peer K; Besnier C; Scher C; Boyle K; Dubbs H; Kramer-Golinkoff J; Pizzino A; Woidill S; Shults J
    N Engl J Med; 2020 Sep; 383(10):986-989. PubMed ID: 32877590
    [No Abstract]   [Full Text] [Related]  

  • 4. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1).
    Meesilpavikkai K; Dik WA; Schrijver B; Nagtzaam NMA; Posthumus-van Sluijs SJ; van Hagen PM; Dalm VASH
    J Allergy Clin Immunol; 2018 Jul; 142(1):328-330.e2. PubMed ID: 29729898
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK-STAT inhibitors for the treatment of immunomediated diseases.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome.
    Boyadzhiev M; Marinov L; Boyadzhiev V; Iotova V; Aksentijevich I; Hambleton S
    Pediatr Rheumatol Online J; 2019 May; 17(1):19. PubMed ID: 31046790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
    Zimmermann N; Wolf C; Schwenke R; Lüth A; Schmidt F; Engel K; Lee-Kirsch MA; Günther C
    JAMA Dermatol; 2019 Mar; 155(3):342-346. PubMed ID: 30673078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repigmentation of vitiligo with oral baricitinib.
    Mumford BP; Gibson A; Chong AH
    Australas J Dermatol; 2020 Nov; 61(4):374-376. PubMed ID: 32491188
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor.
    Wong GN; Lee S; Foley P
    Australas J Dermatol; 2019 Nov; 60(4):e334-e335. PubMed ID: 31012089
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
    Melikhov O; Kruglova T; Lytkina K; Melkonyan G; Prokhorovich E; Putsman G; Rodoman G; Vertkin A; Zagrebneva A; Stebbing J
    Ann Rheum Dis; 2021 Sep; 80(9):1245-1246. PubMed ID: 34099486
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid improvement of refractory generalized granuloma annulare with the Janus kinase inhibitor baricitinib in two patients.
    Kim D; Kang HY
    Clin Exp Dermatol; 2023 Mar; 48(4):375-376. PubMed ID: 36763768
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib.
    Combe B; Balsa A; Sarzi-Puttini P; Tony HP; de la Torre I; Rogai V; Durand F; Witt S; Zhong J; Dougados M
    Ann Rheum Dis; 2019 Aug; 78(8):1135-1138. PubMed ID: 30842122
    [No Abstract]   [Full Text] [Related]  

  • 13. [Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)].
    Alten R; Nitschmann S
    Internist (Berl); 2017 Dec; 58(12):1341-1344. PubMed ID: 29119202
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutières Syndrome, a Type I Interferonopathy.
    Meesilpavikkai K; Dik WA; Schrijver B; van Helden-Meeuwsen CG; Versnel MA; van Hagen PM; Bijlsma EK; Ruivenkamp CAL; Oele MJ; Dalm VASH
    Arthritis Rheumatol; 2019 May; 71(5):829-831. PubMed ID: 30666809
    [No Abstract]   [Full Text] [Related]  

  • 15. Baricitinib in Alopecia Areata.
    Messenger A; Harries M
    N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
    Taylor PC
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic.
    Akiyama S; Yamada A; Sakuraba A
    J Med Virol; 2021 Feb; 93(2):714-716. PubMed ID: 32949157
    [No Abstract]   [Full Text] [Related]  

  • 18. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
    J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of spondyloenchondrodysplasia with baricitinib.
    Shimizu M; Inoue N; Mizuta M; Irabu H; Okajima M; Honda Y; Nihira H; Izawa K; Yachie A; Wada T
    Rheumatology (Oxford); 2021 Feb; 60(2):e44-e46. PubMed ID: 32856090
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.